Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CFIUS Approves Sino Biopharm’s Acquisition of F-Star after Nine Month Wait

publication date: Mar 8, 2023

Sino Biopharm was approved to close its $161 million all-cash acquisition of F-Star, a Cambridge, UK company that develops bispecific antibodies. The purchase didn't look like would happen after it was held up for nine months by the US government’s Committee on Foreign Investment in the United States (CFIUS), which aims to slow China’s acquisition of advanced US technologies. F-Star, which has a NASDAQ listing and a US subsidiary in Cambridge, MA, develops bispecific drugs for immunotherapies using tetravalent (2+2) bispecific antibodies. More details....

Stock Symbols: (HK: 1177) (NSDQ: FSTX)

Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital